Frequently Asked Questions

A CRO selection consultant runs the sponsor side of choosing a contract research organization: defining real scope before the RFP goes out, building objective scoring criteria, pressure-testing proposals and bid-defense claims, and translating the winning proposal into a contract with enforceable governance. The output is a partnership structured for accountability.

Start with choosing the right CRO by scoping the trial's actual complexity, then match it against your own internal capability and governance maturity. Weight therapeutic and modality experience, named staff continuity, quality culture and financial stability above headline price. Verify what you are told through references and past performance data rather than the capabilities deck.

Not always. A single-site first-in-human study at an experienced Phase 1 unit may need vendor coordination rather than a full-service CRO. What decides is not the phase but how much operational infrastructure you have and how much complexity the protocol carries. Buying more CRO than the study needs is a common and expensive first mistake.

Phase 2 is usually where operational complexity first outruns internal capacity: more sites, real enrollment risk, and endpoints that matter to the next financing. Weight therapeutic and indication experience, named staff who will stay with the study, and demonstrated enrollment performance in your population above headline price. Phase 2 failures are more often operational than scientific.

Run properly, from scoping through contract execution, eight to sixteen weeks is typical. Compressing it rarely saves time; it moves the work downstream into change orders and rework. The two stages sponsors shorten most often, scoping before the RFP and reference checking before award, are the two that most reliably prevent later problems.

Beyond capabilities and pricing, an effective RFP asks how the CRO will behave under pressure: staff retention and turnover, named functional leads and their continuity, escalation paths and decision rights, governance cadence, performance metrics, and how database lock actually went on comparable studies.

A structured set of things to verify rather than accept: named functional leads and their real availability, turnover in your therapeutic area, financial stability, quality system and inspection history, data systems and data ownership, subcontractors, and reference studies of comparable complexity. The value is in verifying each item, not in holding the list.

Three recur. Hedged staffing language such as “anticipated” or “subject to availability.” Governance described as “robust” with no decision rights, escalation path or named owners. And assumptions that look aggressive — fast enrollment, thin monitoring — which tend to return later as change orders and deviations.

The meeting where a shortlisted CRO presents its proposal and answers questions. Its real purpose is to meet the people who would actually run your study and test whether the operating model in the deck survives contact with specifics. If the team in the room is not the team named in the contract, that is itself the finding.

Ask for sponsors with comparable studies rather than the CRO's favorite clients, and speak to the operational lead rather than the executive sponsor. Ask what went wrong and how it was handled; every study has something. A reference who cannot name a single difficulty is telling you they were not close enough to the work to know

Full-service delegates an integrated scope to a single CRO, which suits sponsors with thin internal infrastructure but concentrates dependency. FSP contracts specific functions to providers, giving more control while requiring the sponsor to integrate across them. Hybrid blends both. The right choice follows governance maturity, not price.

It depends on how much oversight capacity you genuinely have, not on which model looks cheapest. Full-service asks less day-to-day integration but more governance discipline. FSP demands cross-functional coordination the sponsor must supply. The costliest mistake is picking a model that assumes internal capability you have not built.

Yes, and sponsors regularly do — most often moving from full-service to FSP as internal capability grows. The constraint is governance capacity rather than contracts. Moving to FSP means taking back cross-functional coordination the CRO was absorbing, so the real question is whether you have the people to carry it.

Most combine unit-based direct fees, pass-through costs and investigator grants, built on assumptions about site count, enrollment rate, visit volume and study duration. The fee portion is what gets negotiated; the assumptions are what determine what you actually pay. Interrogating the assumptions is worth more than negotiating the rates.

Almost always a gap between the assumptions in the bid grid and what the study turns out to require: slower enrollment, more sites, longer duration, additional monitoring. Some are legitimate and unavoidable. The avoidable ones come from accepting optimistic assumptions at award because they made the bid look competitive.

No. Contracts establish the commercial and legal foundation, but when timelines slip or enrollment stalls, what determines the outcome is governance - decision rights, metrics that trigger action, escalation pathways and documentation. Contracts are rarely what anyone reaches for when a study is under real pressure.

CRO oversight is the sponsor's system for monitoring and directing delegated work: defined decision rights, a governance cadence tiered to risk, escalation thresholds, metrics tied to action, and documented evidence of decisions taken. Under ICH E6(R3) the sponsor maintains accountability for quality and safety regardless of what is outsourced.

Enough to see risk early and act on it, not more meetings for their own sake. Adding trackers, dashboards and approval layers creates administrative drag without creating control. Tier governance cadence to the study's actual risk profile, with defined escalation thresholds and leading indicators.

Stand up governance before the first issue arrives: decision rights, a meeting cadence tiered to risk, escalation thresholds, and an agreed set of metrics with named owners. Confirm the delivery team matches the contract. Agree how change orders will be raised and reviewed. Governance built during a crisis is always worse than governance built before one.

No. You can outsource execution, but accountability for trial quality and participant safety stays with the sponsor. ICH E6(R3) makes this explicit — a vendor's failure surfaces as a sponsor finding at inspection. That is why a CRO management function is needed even when nearly all delivery is outsourced.

A dedicated sponsor-side capability for overseeing outsourced delivery. The CRO management function sets decision rights, assigns cross-functional ownership, defines escalation protocols and performance metrics, and maintains the tooling — RACIs, governance charters, risk trackers, scorecards — that turns an outsourced program into a managed one.

It needs the function, not necessarily the headcount. Someone has to own decision rights, escalation, metrics and documentation for outsourced delivery. In a company of fifteen people that is usually a defined responsibility carried by an operations leader, supported by structure — a governance charter, a RACI, a scorecard — rather than by a department.

Hiring a CRO management consultant usually occurs at one of three points: before issuing an RFP, while the selection decision is still open; when a program is drifting and governance is not surfacing problems early enough; or ahead of an inspection, when oversight documentation needs to hold up to scrutiny. Earlier is consistently cheaper than later.

Rarely because of bad science. More often a program becomes someone's second priority. CROs read priority from response clarity and executive engagement rather than contract language, so when sponsor decisions slow and escalations go unowned, attention shifts toward programs that are being actively governed.

Tie every metric to a consequence. If a number does not produce a decision, an escalation or a behavior change, it is status reporting. Define escalation thresholds in advance, name an owner and a deadline for each action, and state what success looks like before the next review.

Governance that produces documentation without decisions. Standing meetings with no purpose, minutes with no owner or change of course, escalations nobody holds, metrics reviewed but never acted on. It satisfies an auditor's checklist while delivering none of the protection real oversight is supposed to provide.

A KPI tells you how something performed; a KRI tells you something may be about to go wrong. Enrollment against plan is a KPI. A widening gap between screening and randomization at a subset of sites is a KRI. Oversight built only on KPIs is always looking backwards.

Treat it as a program, not a handover. Map every deliverable, system and dataset the incumbent holds; confirm data ownership and export formats in writing; overlap the two teams long enough for genuine knowledge transfer; and keep the regulatory record continuous. Mid-study transitions are recoverable but never cheap, so compare the cost of transition against the cost of the status quo honestly.

ICH E6(R3) is the revised Good Clinical Practice guideline from the International Council for Harmonisation. It reframes GCP around risk-proportionate quality — critical-to-quality factors, risk-based monitoring, and explicit sponsor accountability for oversight of delegated activities — rather than uniform procedural compliance applied evenly everywhere.

The Principles and Annex 1 have been in effect in the EU since 23 July 2025, and the FDA announced the guidance for industry in September 2025. Annex 2, covering decentralized elements and real-world data, was published on 15 July 2026 and comes into effect in the EU on 15 January 2027. Any trial running into 2027 should be built to Annex 2 now, not retrofitted later.

Annex 2 addresses decentralized trial elements, real-world data and pragmatic trial designs. It was adopted and published by ICH on 3 June 2026. These approaches are increasingly standard, but they raise governance demands: remote visits and data originating outside the traditional site widen the oversight surface considerably.

Four things matter operationally. Quality is designed in at the protocol stage through critical-to-quality factors rather than inspected afterwards. Oversight is expected to be proportionate to risk instead of uniform across every trial. Sponsor accountability for delegated activities is stated explicitly; delegation does not transfer responsibility. And data governance now spans the full data lifecycle, including systems, metadata and audit trails.

Regulators generally expect ongoing trials to move toward the new expectations rather than convert overnight, but findings will be judged against the standard in force at the time of inspection. The practical question is whether your oversight produces evidence of risk-proportionate decisions. Most sponsors can demonstrate that without reopening the protocol.

It makes vendor quality systems a selection criterion rather than a procurement footnote. Because the sponsor retains ownership of trial quality and participant safety, a CRO's failure appears as a sponsor finding. Selection has to assess demonstrated quality culture, and contracts have to secure access to vendor system records.

A quality tolerance limit is a range agreed in advance for a parameter that affects the reliability of the trial result, for instance a screen failure rate or missing primary endpoint data. Breaching it triggers evaluation, not automatic action. The discipline is deciding beforehand what degree of deviation would change how you interpret the study, rather than arguing about it once the data are in.

Directing oversight effort where failure would genuinely threaten participant safety or data integrity, rather than monitoring everything at equal intensity. In practice: identify critical-to-quality factors, size monitoring to them, use central review where it works better, and adjust as the risk picture shifts during the study.

Designing the trial so the things most likely to compromise participant safety or result reliability are addressed in the protocol rather than managed later through monitoring. In practice that means identifying critical-to-quality factors before the protocol is final and removing complexity that adds operational risk without adding evidence.

The attributes of a trial where a failure would meaningfully compromise participant safety or the reliability of the results. Identifying them early is what makes proportional monitoring possible — it tells a lean team where to concentrate limited oversight capacity and where a lighter touch is defensible.

Reviewing accumulating data centrally, across sites and over time, to detect patterns an on-site visit would miss, such as implausible distributions, unusual timing, sites that behave differently from their peers. Under a risk-based approach it frequently finds more than proportional on-site review, and it lets a lean team concentrate site visits where the data says to look.

Build the record as the study runs rather than reconstructing it afterward. Keep contemporaneous decision logs, KPI and KRI outputs with trend analysis, issue and escalation logs, and documented vendor selection rationale. Inspectors look for evidence of deliberate, ongoing oversight, not a file assembled at the end.

A fractional clinical operations executive is a senior clinical operations leader engaged part-time, typically on monthly retainer, who takes real accountability rather than advising from the outside. Scope usually covers organizational and governance design, executive decision support across delivery and vendor management, and representation at board or sponsor level.

A company needs fractional leadership commonly during growth that has outpaced structure, a leadership gap or transition, a restructuring, or an inspection. The need is for senior judgment and accountability at a volume that does not yet justify a full-time executive hire.

A consultant recommends; a fractional executive owns outcomes. The engagement carries decision authority, accountability for delivery, and a seat in the governance forums where decisions actually get made rather than a report handed over at the end.

Owns how the clinical program gets delivered: operating model, vendor strategy and oversight, budgets and timelines, functional leadership, and the operational input into development decisions. In a small biotech the role is less about managing a large team and more about ensuring outsourced delivery is being governed.

Usually before the first pivotal-intent study, and earlier than most companies expect. The trigger is not headcount; it is the point where operational decisions start carrying development consequences. Many companies bridge the gap with fractional leadership until the workload justifies a full-time hire.

Clinical operators need the leadership skills that surface under delivery pressure: holding results-accountability rather than activity-reporting, having difficult conversations, negotiating with vendors and internal stakeholders, thinking critically under uncertainty, and carrying executive presence across cross-functional, multi-regional teams.

Shift the unit of accountability from activity to results. Reporting what was done is not the same as owning what was achieved. That requires explicit ownership, the skill to raise problems early rather than at the milestone, and leaders willing to have the conversation when a commitment slips.